Dabrafenib/dabrafenib targeted drug price list

Dabrafenib is an oral, small molecule inhibitor of certain mutant forms of braf kinase. BRAF is a subtype of RAF whose mutated form can lead to dysregulated cell growth, leading to tumor progression. Clinical trials of dabrafenib in patients with advanced melanoma have shown that it can extend progression-free survival in humans, but this effect appears to be limited to patients with the BRAF V600E mutation. Dabrafenib was approved for use in the United States in 2013, and its combination with trametinib (a inhibitor of MEK, a kinase active downstream of BRAF in the MAP kinase pathway) was approved for use in in 2014.

Currently, dabrafenib is considered a single drug for the treatment of unresectable or metastatic melanoma with BRAF V600E mutations, and is used in combination with trimetinib to treat patients with advanced melanoma, non-small cell lung cancer, and thyroid cancer with BRAF V600E or V600K mutations. Dabrafenib is available in 50 and 75 mg capsules under the brand name Tafinlar. The recommended dose is 150 mg taken orally twice daily. Common side effects include hyperkeratosis, rash, headache, fever, alopecia, and peripheral neuropathy.

The original version of dabrafenib has been officially launched in China and is included in the scope of medical insurance. Its mainstream specifications include50 mg 120 tablets and 75 mg 120 tablets. Each box may be sold for more than 10,000 yuan. Overseas, especially in Turkey, the original research version of dabrafenib in a 75 mg 120-pellet package is priced at about more than 7,000 yuan, but exchange rate changes may cause price fluctuations. In addition, there are many generic versions of dabrafenib in overseas markets. The ingredients of the drug are similar to the original drug. For example, drugs of the same specifications produced in Laos may be more affordable, about more than 2,000 yuan, but they are also affected by the exchange rate.